Business News Agency March 2 hearing because of the lack of evidence that bevacizumab (bevacizumab, trade name Avastin) is safe and effective for breast cancer patients, the Beijing Drug Administration has recently issued a pharmacovigilance newsletter proposal from Bevac Deletion of breast cancer indications in the specification of zumab.

According to information provided by the Beijing Municipal Food and Drug Administration, the US Food and Drug Administration (FDA) recently reviewed the results of four clinical studies of bevacizumab used to treat breast cancer. There is clear data that this drug cannot prolong breast cancer. The FDA made the above recommendations after the patient’s overall survival, or in terms of slowing the progression of the disease, failed to provide patients with benefits that exceeded their risk. The risks of using bevacizumab include: severe high blood pressure, bleeding and bleeding, perforation of the nose, stomach, intestines, heart attack, or heart failure.

FDA test data also showed that bevacizumab is also associated with several other serious side effects, including stroke, wound complications, organ damage or functional failure, reversible posterior cerebral white encephalopathy syndrome, and high blood pressure, headache , mental confusion, seizures, brain edema caused by loss of vision as the main feature. Based on all the data concerning the use of bevacizumab in the treatment of metastatic breast cancer, the FDA has determined that the risk of this drug exceeds the benefit.